245 related articles for article (PubMed ID: 25601485)
1. Targeting HER2 in the treatment of non-small cell lung cancer.
Mar N; Vredenburgh JJ; Wasser JS
Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
[TBL] [Abstract][Full Text] [Related]
2. Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
Nützinger J; Bum Lee J; Li Low J; Ling Chia P; Talisa Wijaya S; Chul Cho B; Min Lim S; Soo RA
Lung Cancer; 2023 Dec; 186():107385. PubMed ID: 37813015
[TBL] [Abstract][Full Text] [Related]
3. [Current Status and Issues of Companion Diagnostics for Non-Small Cell Lung Cancer].
Satouchi M
Gan To Kagaku Ryoho; 2024 Apr; 51(4):378-382. PubMed ID: 38644300
[TBL] [Abstract][Full Text] [Related]
4. The application of HER2-ADC in future: More than expression.
Zhou J; He H; Wang S; Li N
Med; 2024 Mar; 5(3):173-175. PubMed ID: 38460494
[TBL] [Abstract][Full Text] [Related]
5. ERBB2 Amplification in NSCLC: How Many Faces?
Shih JY
J Thorac Oncol; 2024 May; 19(5):668-670. PubMed ID: 38719422
[No Abstract] [Full Text] [Related]
6. HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies.
Loeffler E; Ancel J; Dalstein V; Deslée G; Polette M; Nawrocki-Raby B
Life (Basel); 2023 Dec; 14(1):. PubMed ID: 38255679
[TBL] [Abstract][Full Text] [Related]
7. HER2 mutation as an emerging target in advanced breast cancer.
Bon G; Di Lisa FS; Filomeno L; Arcuri T; Krasniqi E; Pizzuti L; Barba M; Messina B; Schiavoni G; Sanguineti G; Botti C; Cappelli S; Pelle F; Cavicchi F; Puccica I; Costantini M; Perracchio L; Maugeri-Saccà M; Ciliberto G; Vici P
Cancer Sci; 2024 May; ():. PubMed ID: 38715247
[TBL] [Abstract][Full Text] [Related]
8. HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.
Li BT; Ross DS; Aisner DL; Chaft JE; Hsu M; Kako SL; Kris MG; Varella-Garcia M; Arcila ME
J Thorac Oncol; 2016 Mar; 11(3):414-9. PubMed ID: 26723242
[TBL] [Abstract][Full Text] [Related]
9. Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation.
Mar N; Vredenburgh JJ
Conn Med; 2015 Oct; 79(9):531-5. PubMed ID: 26630704
[TBL] [Abstract][Full Text] [Related]
10. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
Pillai RN; Behera M; Berry LD; Rossi MR; Kris MG; Johnson BE; Bunn PA; Ramalingam SS; Khuri FR
Cancer; 2017 Nov; 123(21):4099-4105. PubMed ID: 28743157
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy in NSCLC driven by HER2 insertions.
Peters S; Zimmermann S
Transl Lung Cancer Res; 2014 Apr; 3(2):84-8. PubMed ID: 25806285
[TBL] [Abstract][Full Text] [Related]
12. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Mazières J; Barlesi F; Filleron T; Besse B; Monnet I; Beau-Faller M; Peters S; Dansin E; Früh M; Pless M; Rosell R; Wislez M; Fournel P; Westeel V; Cappuzzo F; Cortot A; Moro-Sibilot D; Milia J; Gautschi O
Ann Oncol; 2016 Feb; 27(2):281-6. PubMed ID: 26598547
[TBL] [Abstract][Full Text] [Related]
13. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
14. ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Chuang JC; Stehr H; Liang Y; Das M; Huang J; Diehn M; Wakelee HA; Neal JW
J Thorac Oncol; 2017 May; 12(5):833-842. PubMed ID: 28167203
[TBL] [Abstract][Full Text] [Related]
15. [Advances on driver oncogenes of non-small cell lung cancer].
Zhao J; Xiong J
Zhongguo Fei Ai Za Zhi; 2015 Jan; 18(1):42-7. PubMed ID: 25603872
[TBL] [Abstract][Full Text] [Related]
16. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
Kris MG; Camidge DR; Giaccone G; Hida T; Li BT; O'Connell J; Taylor I; Zhang H; Arcila ME; Goldberg Z; Jänne PA
Ann Oncol; 2015 Jul; 26(7):1421-7. PubMed ID: 25899785
[TBL] [Abstract][Full Text] [Related]
17. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Li BT; Shen R; Buonocore D; Olah ZT; Ni A; Ginsberg MS; Ulaner GA; Offin M; Feldman D; Hembrough T; Cecchi F; Schwartz S; Pavlakis N; Clarke S; Won HH; Brzostowski EB; Riely GJ; Solit DB; Hyman DM; Drilon A; Rudin CM; Berger MF; Baselga J; Scaltriti M; Arcila ME; Kris MG
J Clin Oncol; 2018 Aug; 36(24):2532-2537. PubMed ID: 29989854
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.
Hotta K; Aoe K; Kozuki T; Ohashi K; Ninomiya K; Ichihara E; Kubo T; Ninomiya T; Chikamori K; Harada D; Nogami N; Hirata T; Hinotsu S; Toyooka S; Kiura K
J Thorac Oncol; 2018 Feb; 13(2):273-279. PubMed ID: 29313813
[TBL] [Abstract][Full Text] [Related]
19. HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
Reis H; Herold T; Ting S; Worm K; Huber U; Christoph DC; Eberhardt WE; Kostbade K; Kasper S; Stamatis G; Welter S; Darwiche K; Karpf-Wissel R; Theegarten D; Schmid KW; Schuler M; Wiesweg M
Lung Cancer; 2015 Apr; 88(1):34-41. PubMed ID: 25708529
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.
Besse B; Le Moulec S; Mazières J; Senellart H; Barlesi F; Chouaid C; Dansin E; Bérard H; Falchero L; Gervais R; Robinet G; Ruppert AM; Schott R; Léna H; Clément-Duchêne C; Quantin X; Souquet PJ; Trédaniel J; Moro-Sibilot D; Pérol M; Madroszyk AC; Soria JC
Clin Cancer Res; 2015 Apr; 21(8):1896-903. PubMed ID: 25614446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]